Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0039-1693660 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction to: Double-territory STEMI with cardiogenic shock in immune thrombocytopenic purpura with severe thrombocytopenia-a case report.
Eur Heart J Case Rep
September 2024
[This corrects the article DOI: 10.1093/ehjcr/ytae345.].
View Article and Find Full Text PDFDouble-territory STEMI with cardiogenic shock in immune thrombocytopenic purpura with severe thrombocytopenia-a case report.
Eur Heart J Case Rep
July 2024
Department of Medical Services, Apollo Hospitals, 21, Greams Lane, Off Greams Road, Thousand Lights, Chennai, Tamil Nadu 600006, India.
Background: Myocardial infarction (MI) in a patient with immune thrombocytopenia is a rare scenario which is very challenging to manage.
Case Summary: We present a rare case of a patient with immune thrombocytopenic purpura who developed double territory segment-elevation MI with cardiogenic shock. She had an extremely rare presentation with a fresh mobile thrombus in the aortic root which was trap-dooring the right coronary artery ostium and extending into the artery with an embolism into the distal left anterior descending artery.
Efficacy of thrombopoietin receptor agonists versus rituximab in non-responsive immune thrombocytopenia-A single centre retrospective analysis.
Br J Haematol
September 2024
Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland.
Management of immune thrombocytopenia (ITP) beyond initial glucocorticoid therapy is challenging. In this retrospective single-centre cohort study, we compared all ITP patients relapsed or non-responsive to glucocorticoid therapy treated with either continuous TPO-RAs (n = 35) or rituximab induction (n = 20) between 2015 and 2022. While both groups showed high initial complete response rates (CR, 68.
View Article and Find Full Text PDFRisk of fractures and use of bisphosphonates in adult patients with immune thrombocytopenia-A nationwide population-based study.
Br J Haematol
April 2024
Department of Haematology, Odense University Hospital, Odense, Denmark.
Corticosteroids remain the first-line treatment of immune thrombocytopenia (ITP), but increase the risk of osteoporosis and fractures. Bisphosphonates are used for the treatment of osteoporosis, but their usage among patients with ITP has not been systemically described. We investigated the risk of fractures and the use of bisphosphonates in adult patients with primary (pITP) and secondary ITP (sITP) compared with matched comparators in a nationwide registry-based cohort study.
View Article and Find Full Text PDFEarly immunomodulation in immune thrombocytopenia-A report of the ICIS meeting in Lenzerheide, Switzerland 2022.
Br J Haematol
October 2023
Department of Haematology/Oncology, University Children's Hospital Basel, Basel, Switzerland.
The only way to prevent immune thrombocytopenia (ITP) from becoming refractory would be to restore tolerance to platelets at an early phase of the disease. Numerous immune alterations probably accumulate in chronic ITP; thus, the chances of cure decrease significantly with time. Currently, sustained remission off treatment (SROT) is a clinical definition describing patients who can discontinue their ITP treatment without risk and maintain a state of remission.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!